Scancell Holdings plc
LSE: SCLP.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Phillip John L'Huillier
- Employees
- 61
- Headquarters
- Oxford, United Kingdom
- IPO year
- 2010
- Market cap
- £176.4M
- Website
- https://www.scancell.co.uk
Loading SCLP…
Loading profile data…Frequently asked questions about SCLP
What does Scancell Holdings plc (SCLP.L) do?
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the tr...
Where does SCLP.L trade?
Scancell Holdings plc (SCLP.L) trades on the London Stock Exchange.
What sector is SCLP.L in?
Scancell Holdings plc (SCLP.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Scancell Holdings plc?
Phillip John L'Huillier is the chief executive officer of Scancell Holdings plc (SCLP.L).
Where is Scancell Holdings plc headquartered?
Scancell Holdings plc is headquartered in United Kingdom.
Does SCLP.L pay a dividend?
Scancell Holdings plc (SCLP.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SCLP.L go public?
Scancell Holdings plc (SCLP.L) completed its initial public offering in 2010.